XML 78 R67.htm IDEA: XBRL DOCUMENT
v3.21.1

Segment Reporting - Sales of Company's Products (Details) - USD ($) $ in Millions | 3 Months Ended
--- | ---
Mar. 31, 2021 | Mar. 31, 2020
Segment Reporting Information [Line Items] |  |
Sales | $ 12,080 | $ 12,057
Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 12,093 | 11,892
Other |  |
Segment Reporting Information [Line Items] |  |
Sales | (13) | 165
United States |  |
Segment Reporting Information [Line Items] |  |
Sales | 5,136 | 5,137
United States | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 5,078 | 5,121
United States | Other |  |
Segment Reporting Information [Line Items] |  |
Sales | 58 | 16
International |  |
Segment Reporting Information [Line Items] |  |
Sales | 6,943 | 6,920
International | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 7,015 | 6,771
International | Other |  |
Segment Reporting Information [Line Items] |  |
Sales | (72) | 149
Total Pharmaceutical segment sales | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 10,675 | 10,655
Total Pharmaceutical segment sales | Operating Segments | Keytruda |  |
Segment Reporting Information [Line Items] |  |
Sales | 3,899 | 3,284
Total Pharmaceutical segment sales | Operating Segments | Alliance revenue - Lynparza (1) |  |
Segment Reporting Information [Line Items] |  |
Sales | 228 | 145
Total Pharmaceutical segment sales | Operating Segments | Alliance revenue - Lenvima (1) |  |
Segment Reporting Information [Line Items] |  |
Sales | 130 | 128
Total Pharmaceutical segment sales | Operating Segments | Gardasil/Gardasil 9 |  |
Segment Reporting Information [Line Items] |  |
Sales | 917 | 1,097
Total Pharmaceutical segment sales | Operating Segments | ProQuad/M-M-R II/Varivax |  |
Segment Reporting Information [Line Items] |  |
Sales | 449 | 435
Total Pharmaceutical segment sales | Operating Segments | Pneumovax 23 |  |
Segment Reporting Information [Line Items] |  |
Sales | 171 | 256
Total Pharmaceutical segment sales | Operating Segments | RotaTeq |  |
Segment Reporting Information [Line Items] |  |
Sales | 158 | 222
Total Pharmaceutical segment sales | Operating Segments | Vaqta |  |
Segment Reporting Information [Line Items] |  |
Sales | 34 | 60
Total Pharmaceutical segment sales | Operating Segments | Bridion |  |
Segment Reporting Information [Line Items] |  |
Sales | 340 | 299
Total Pharmaceutical segment sales | Operating Segments | Prevymis |  |
Segment Reporting Information [Line Items] |  |
Sales | 82 | 60
Total Pharmaceutical segment sales | Operating Segments | Noxafil |  |
Segment Reporting Information [Line Items] |  |
Sales | 67 | 94
Total Pharmaceutical segment sales | Operating Segments | Primaxin |  |
Segment Reporting Information [Line Items] |  |
Sales | 65 | 51
Total Pharmaceutical segment sales | Operating Segments | Cancidas |  |
Segment Reporting Information [Line Items] |  |
Sales | 57 | 55
Total Pharmaceutical segment sales | Operating Segments | Invanz |  |
Segment Reporting Information [Line Items] |  |
Sales | 57 | 64
Total Pharmaceutical segment sales | Operating Segments | Zerbaxa |  |
Segment Reporting Information [Line Items] |  |
Sales | (8) | 37
Total Pharmaceutical segment sales | Operating Segments | Simponi |  |
Segment Reporting Information [Line Items] |  |
Sales | 214 | 215
Total Pharmaceutical segment sales | Operating Segments | Remicade |  |
Segment Reporting Information [Line Items] |  |
Sales | 85 | 88
Total Pharmaceutical segment sales | Operating Segments | Belsomra |  |
Segment Reporting Information [Line Items] |  |
Sales | 79 | 79
Total Pharmaceutical segment sales | Operating Segments | Isentress/Isentress HD |  |
Segment Reporting Information [Line Items] |  |
Sales | 209 | 245
Total Pharmaceutical segment sales | Operating Segments | Zetia |  |
Segment Reporting Information [Line Items] |  |
Sales | 92 | 145
Total Pharmaceutical segment sales | Operating Segments | Vytorin |  |
Segment Reporting Information [Line Items] |  |
Sales | 41 | 53
Total Pharmaceutical segment sales | Operating Segments | Atozet |  |
Segment Reporting Information [Line Items] |  |
Sales | 112 | 122
Total Pharmaceutical segment sales | Operating Segments | Alliance revenue - Adempas (2) |  |
Segment Reporting Information [Line Items] |  |
Sales | 74 | 53
Total Pharmaceutical segment sales | Operating Segments | Adempas |  |
Segment Reporting Information [Line Items] |  |
Sales | 55 | 56
Total Pharmaceutical segment sales | Operating Segments | Januvia |  |
Segment Reporting Information [Line Items] |  |
Sales | 809 | 774
Total Pharmaceutical segment sales | Operating Segments | Janumet |  |
Segment Reporting Information [Line Items] |  |
Sales | 486 | 503
Total Pharmaceutical segment sales | Operating Segments | Implanon/Nexplanon |  |
Segment Reporting Information [Line Items] |  |
Sales | 183 | 195
Total Pharmaceutical segment sales | Operating Segments | NuvaRing |  |
Segment Reporting Information [Line Items] |  |
Sales | 45 | 63
Total Pharmaceutical segment sales | Operating Segments | Singulair |  |
Segment Reporting Information [Line Items] |  |
Sales | 107 | 155
Total Pharmaceutical segment sales | Operating Segments | Cozaar/Hyzaar |  |
Segment Reporting Information [Line Items] |  |
Sales | 90 | 102
Total Pharmaceutical segment sales | Operating Segments | Arcoxia |  |
Segment Reporting Information [Line Items] |  |
Sales | 56 | 70
Total Pharmaceutical segment sales | Operating Segments | Follistim AQ |  |
Segment Reporting Information [Line Items] |  |
Sales | 52 | 41
Total Pharmaceutical segment sales | Operating Segments | Nasonex |  |
Segment Reporting Information [Line Items] |  |
Sales | 43 | 71
Total Pharmaceutical segment sales | Operating Segments | Other pharmaceutical (3) |  |
Segment Reporting Information [Line Items] |  |
Sales | 1,197 | 1,338
Total Pharmaceutical segment sales | United States | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 4,641 | 4,714
Total Pharmaceutical segment sales | United States | Operating Segments | Keytruda |  |
Segment Reporting Information [Line Items] |  |
Sales | 2,181 | 1,906
Total Pharmaceutical segment sales | United States | Operating Segments | Alliance revenue - Lynparza (1) |  |
Segment Reporting Information [Line Items] |  |
Sales | 118 | 85
Total Pharmaceutical segment sales | United States | Operating Segments | Alliance revenue - Lenvima (1) |  |
Segment Reporting Information [Line Items] |  |
Sales | 85 | 90
Total Pharmaceutical segment sales | United States | Operating Segments | Gardasil/Gardasil 9 |  |
Segment Reporting Information [Line Items] |  |
Sales | 313 | 461
Total Pharmaceutical segment sales | United States | Operating Segments | ProQuad/M-M-R II/Varivax |  |
Segment Reporting Information [Line Items] |  |
Sales | 333 | 333
Total Pharmaceutical segment sales | United States | Operating Segments | Pneumovax 23 |  |
Segment Reporting Information [Line Items] |  |
Sales | 73 | 182
Total Pharmaceutical segment sales | United States | Operating Segments | RotaTeq |  |
Segment Reporting Information [Line Items] |  |
Sales | 118 | 140
Total Pharmaceutical segment sales | United States | Operating Segments | Vaqta |  |
Segment Reporting Information [Line Items] |  |
Sales | 25 | 30
Total Pharmaceutical segment sales | United States | Operating Segments | Bridion |  |
Segment Reporting Information [Line Items] |  |
Sales | 167 | 143
Total Pharmaceutical segment sales | United States | Operating Segments | Prevymis |  |
Segment Reporting Information [Line Items] |  |
Sales | 35 | 26
Total Pharmaceutical segment sales | United States | Operating Segments | Noxafil |  |
Segment Reporting Information [Line Items] |  |
Sales | 15 | 8
Total Pharmaceutical segment sales | United States | Operating Segments | Primaxin |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Cancidas |  |
Segment Reporting Information [Line Items] |  |
Sales | 3 | 3
Total Pharmaceutical segment sales | United States | Operating Segments | Invanz |  |
Segment Reporting Information [Line Items] |  |
Sales | 4 | 6
Total Pharmaceutical segment sales | United States | Operating Segments | Zerbaxa |  |
Segment Reporting Information [Line Items] |  |
Sales | (2) | 20
Total Pharmaceutical segment sales | United States | Operating Segments | Simponi |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Remicade |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Belsomra |  |
Segment Reporting Information [Line Items] |  |
Sales | 18 | 27
Total Pharmaceutical segment sales | United States | Operating Segments | Isentress/Isentress HD |  |
Segment Reporting Information [Line Items] |  |
Sales | 71 | 75
Total Pharmaceutical segment sales | United States | Operating Segments | Zetia |  |
Segment Reporting Information [Line Items] |  |
Sales | 2 | (2)
Total Pharmaceutical segment sales | United States | Operating Segments | Vytorin |  |
Segment Reporting Information [Line Items] |  |
Sales | 2 | 3
Total Pharmaceutical segment sales | United States | Operating Segments | Atozet |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Alliance revenue - Adempas (2) |  |
Segment Reporting Information [Line Items] |  |
Sales | 68 | 49
Total Pharmaceutical segment sales | United States | Operating Segments | Adempas |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Januvia |  |
Segment Reporting Information [Line Items] |  |
Sales | 348 | 355
Total Pharmaceutical segment sales | United States | Operating Segments | Janumet |  |
Segment Reporting Information [Line Items] |  |
Sales | 84 | 113
Total Pharmaceutical segment sales | United States | Operating Segments | Implanon/Nexplanon |  |
Segment Reporting Information [Line Items] |  |
Sales | 141 | 149
Total Pharmaceutical segment sales | United States | Operating Segments | NuvaRing |  |
Segment Reporting Information [Line Items] |  |
Sales | 21 | 26
Total Pharmaceutical segment sales | United States | Operating Segments | Singulair |  |
Segment Reporting Information [Line Items] |  |
Sales | 4 | 5
Total Pharmaceutical segment sales | United States | Operating Segments | Cozaar/Hyzaar |  |
Segment Reporting Information [Line Items] |  |
Sales | 3 | 7
Total Pharmaceutical segment sales | United States | Operating Segments | Arcoxia |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Follistim AQ |  |
Segment Reporting Information [Line Items] |  |
Sales | 25 | 21
Total Pharmaceutical segment sales | United States | Operating Segments | Nasonex |  |
Segment Reporting Information [Line Items] |  |
Sales | 2 | 6
Total Pharmaceutical segment sales | United States | Operating Segments | Other pharmaceutical (3) |  |
Segment Reporting Information [Line Items] |  |
Sales | 384 | 447
Total Pharmaceutical segment sales | International | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 6,034 | 5,941
Total Pharmaceutical segment sales | International | Operating Segments | Keytruda |  |
Segment Reporting Information [Line Items] |  |
Sales | 1,718 | 1,378
Total Pharmaceutical segment sales | International | Operating Segments | Alliance revenue - Lynparza (1) |  |
Segment Reporting Information [Line Items] |  |
Sales | 110 | 60
Total Pharmaceutical segment sales | International | Operating Segments | Alliance revenue - Lenvima (1) |  |
Segment Reporting Information [Line Items] |  |
Sales | 44 | 38
Total Pharmaceutical segment sales | International | Operating Segments | Gardasil/Gardasil 9 |  |
Segment Reporting Information [Line Items] |  |
Sales | 604 | 636
Total Pharmaceutical segment sales | International | Operating Segments | ProQuad/M-M-R II/Varivax |  |
Segment Reporting Information [Line Items] |  |
Sales | 117 | 102
Total Pharmaceutical segment sales | International | Operating Segments | Pneumovax 23 |  |
Segment Reporting Information [Line Items] |  |
Sales | 99 | 75
Total Pharmaceutical segment sales | International | Operating Segments | RotaTeq |  |
Segment Reporting Information [Line Items] |  |
Sales | 41 | 82
Total Pharmaceutical segment sales | International | Operating Segments | Vaqta |  |
Segment Reporting Information [Line Items] |  |
Sales | 9 | 30
Total Pharmaceutical segment sales | International | Operating Segments | Bridion |  |
Segment Reporting Information [Line Items] |  |
Sales | 173 | 157
Total Pharmaceutical segment sales | International | Operating Segments | Prevymis |  |
Segment Reporting Information [Line Items] |  |
Sales | 47 | 33
Total Pharmaceutical segment sales | International | Operating Segments | Noxafil |  |
Segment Reporting Information [Line Items] |  |
Sales | 52 | 87
Total Pharmaceutical segment sales | International | Operating Segments | Primaxin |  |
Segment Reporting Information [Line Items] |  |
Sales | 65 | 51
Total Pharmaceutical segment sales | International | Operating Segments | Cancidas |  |
Segment Reporting Information [Line Items] |  |
Sales | 55 | 52
Total Pharmaceutical segment sales | International | Operating Segments | Invanz |  |
Segment Reporting Information [Line Items] |  |
Sales | 52 | 59
Total Pharmaceutical segment sales | International | Operating Segments | Zerbaxa |  |
Segment Reporting Information [Line Items] |  |
Sales | (6) | 16
Total Pharmaceutical segment sales | International | Operating Segments | Simponi |  |
Segment Reporting Information [Line Items] |  |
Sales | 214 | 215
Total Pharmaceutical segment sales | International | Operating Segments | Remicade |  |
Segment Reporting Information [Line Items] |  |
Sales | 85 | 88
Total Pharmaceutical segment sales | International | Operating Segments | Belsomra |  |
Segment Reporting Information [Line Items] |  |
Sales | 61 | 53
Total Pharmaceutical segment sales | International | Operating Segments | Isentress/Isentress HD |  |
Segment Reporting Information [Line Items] |  |
Sales | 138 | 170
Total Pharmaceutical segment sales | International | Operating Segments | Zetia |  |
Segment Reporting Information [Line Items] |  |
Sales | 90 | 147
Total Pharmaceutical segment sales | International | Operating Segments | Vytorin |  |
Segment Reporting Information [Line Items] |  |
Sales | 38 | 50
Total Pharmaceutical segment sales | International | Operating Segments | Atozet |  |
Segment Reporting Information [Line Items] |  |
Sales | 112 | 122
Total Pharmaceutical segment sales | International | Operating Segments | Alliance revenue - Adempas (2) |  |
Segment Reporting Information [Line Items] |  |
Sales | 6 | 5
Total Pharmaceutical segment sales | International | Operating Segments | Adempas |  |
Segment Reporting Information [Line Items] |  |
Sales | 55 | 56
Total Pharmaceutical segment sales | International | Operating Segments | Januvia |  |
Segment Reporting Information [Line Items] |  |
Sales | 461 | 419
Total Pharmaceutical segment sales | International | Operating Segments | Janumet |  |
Segment Reporting Information [Line Items] |  |
Sales | 401 | 390
Total Pharmaceutical segment sales | International | Operating Segments | Implanon/Nexplanon |  |
Segment Reporting Information [Line Items] |  |
Sales | 42 | 45
Total Pharmaceutical segment sales | International | Operating Segments | NuvaRing |  |
Segment Reporting Information [Line Items] |  |
Sales | 24 | 37
Total Pharmaceutical segment sales | International | Operating Segments | Singulair |  |
Segment Reporting Information [Line Items] |  |
Sales | 102 | 151
Total Pharmaceutical segment sales | International | Operating Segments | Cozaar/Hyzaar |  |
Segment Reporting Information [Line Items] |  |
Sales | 87 | 95
Total Pharmaceutical segment sales | International | Operating Segments | Arcoxia |  |
Segment Reporting Information [Line Items] |  |
Sales | 56 | 70
Total Pharmaceutical segment sales | International | Operating Segments | Follistim AQ |  |
Segment Reporting Information [Line Items] |  |
Sales | 27 | 21
Total Pharmaceutical segment sales | International | Operating Segments | Nasonex |  |
Segment Reporting Information [Line Items] |  |
Sales | 41 | 65
Total Pharmaceutical segment sales | International | Operating Segments | Other pharmaceutical (3) |  |
Segment Reporting Information [Line Items] |  |
Sales | 814 | 886
Total Animal Health segment sales | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 1,418 | 1,214
Total Animal Health segment sales | Operating Segments | Livestock |  |
Segment Reporting Information [Line Items] |  |
Sales | 819 | 739
Total Animal Health segment sales | Operating Segments | Companion Animals |  |
Segment Reporting Information [Line Items] |  |
Sales | 599 | 475
Total Animal Health segment sales | United States | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 437 | 384
Total Animal Health segment sales | United States | Operating Segments | Livestock |  |
Segment Reporting Information [Line Items] |  |
Sales | 157 | 162
Total Animal Health segment sales | United States | Operating Segments | Companion Animals |  |
Segment Reporting Information [Line Items] |  |
Sales | 280 | 222
Total Animal Health segment sales | International | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 981 | 830
Total Animal Health segment sales | International | Operating Segments | Livestock |  |
Segment Reporting Information [Line Items] |  |
Sales | 662 | 577
Total Animal Health segment sales | International | Operating Segments | Companion Animals |  |
Segment Reporting Information [Line Items] |  |
Sales | 319 | 253
Other segment sales (4) | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 23
Other segment sales (4) | United States | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 23
Other segment sales (4) | International | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | $ 0 | $ 0

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=mrk_InternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LenvimaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_Pneumovax23Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RotateqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VaqtaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrevymisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NoxafilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrimaxinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CancidasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_InvanzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZerbaxaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SimponiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BelsomraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZetiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VytorinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AtozetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanuviaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanumetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ImplanonNexplanonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NuvaringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SingulairMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NasonexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ArcoxiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_FollistimAqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CozaarHyzaarMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LivestockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CompanionAnimalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |